Stigma and efficacy beliefs regarding opioid use disorder treatment and naloxone in communities participating in the HEALing Communities Study intervention

PLoS One. 2024 Dec 4;19(12):e0308965. doi: 10.1371/journal.pone.0308965. eCollection 2024.

Abstract

Background: The HEALing Communities Study (HCS) included health campaigns as part of a community-engaged intervention to reduce opioid-related overdose deaths in 67 highly impacted communities across Kentucky, Massachusetts, New York, and Ohio. Five campaigns were developed with community input to provide information on opioid use disorder (OUD) and overdose prevention, reduce stigma, and build demand for evidence-based practices (EBPs). An evaluation examined the recognition of campaign messages about naloxone and whether stigma and efficacy beliefs regarding OUD treatment and naloxone changed in HCS intervention communities.

Methods: Data were collected through surveys offered on Facebook/Instagram to members of communities participating in the HCS intervention and wait-list control communities.

Results: Participants in HCS intervention communities reported a reduction in stigma regarding OUD and increased efficacy beliefs regarding naloxone associated with recognition of campaign messages. However, this finding is cautiously interpreted as there was no clear evidence for recognition differences between the treatment/control conditions.

Conclusion: Study findings indicate associations between campaign message recognition and positive outcomes. Results also highlight possible challenges concerning evaluations of social media campaigns using conventional evaluation techniques.

Trial registration: ClinicalTrials.gov NCT04111939.

Publication types

  • Clinical Study

MeSH terms

  • Adult
  • Female
  • Health Knowledge, Attitudes, Practice
  • Health Promotion / methods
  • Humans
  • Kentucky
  • Male
  • Massachusetts
  • Middle Aged
  • Naloxone* / therapeutic use
  • Narcotic Antagonists / therapeutic use
  • New York
  • Ohio
  • Opioid-Related Disorders* / drug therapy
  • Opioid-Related Disorders* / psychology
  • Social Media
  • Social Stigma*
  • Surveys and Questionnaires
  • Young Adult

Substances

  • Naloxone
  • Narcotic Antagonists

Associated data

  • ClinicalTrials.gov/NCT04111939

Grants and funding

All authors were supported via funding. Employees of the sponsors played a role in the study design, data collection and analysis, decision to publish, and preparation of the manuscript. https://www.nih.gov/https://www.samhsa.gov/ Funding: This research was supported by the National Institutes of Health (NIH) and the Substance Abuse and Mental Health Services Administration through the NIH HEAL (Helping to End Addiction Long-termSM) Initiative under award numbers UM1DA049394, UM1DA049406, UM1DA049412, UM1DA049415, UM1DA049417 (ClinicalTrials.gov Identifier: NCT04111939). This study protocol (Pro00038088) was approved by Advarra Inc., the HEALing Communities Study single Institutional Review Board. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Substance Abuse and Mental Health Services Administration or the NIH HEAL InitiativeSM. Dr. Chandler participated in this paper consistent with her role as a NIH Science Officer.